Unknown

Dataset Information

0

Optimal use of raltegravir (Isentress(R)) in the treatment of HIV-infected adults - Canadian consensus guidelines.


ABSTRACT: BACKGROUND AND OBJECTIVES:A meeting of a Canadian group with significant experience and knowledge in HIV management, consisting of five physicians, a pharmacist and an AIDS researcher, was convened. Their goal was to develop guidance for Canadian HIV-treating physicians on the appropriate use of raltegravir (MK-0518, Isentress(R), Merck Frosst Canada Inc) in HIV-infected adults. METHODS:Evidence from the published literature and conference presentations, as well as expert opinions of the group members, was considered and evaluated to develop the recommendations. Feedback on the draft recommendations was obtained from this core group, as well as from five other physicians and scientists across Canada with expertise in HIV treatment and antiretroviral drug resistance, and experience in the use of raltegravir. The final recommendations represent the core group's consensus agreement once all feedback was considered. RESULTS/CONCLUSIONS:Recommendations were developed to guide physicians in the optimal use of raltegravir. The issues considered included raltegravir's role in overall treatment strategy, efficacy, durability of effect, rate of viral load reduction, resistance, safety/toxicity, pharmacokinetics and drug interactions.

SUBMITTER: Rachlis A 

PROVIDER: S-EPMC2770304 | biostudies-literature | 2009

REPOSITORIES: biostudies-literature

altmetric image

Publications

Optimal use of raltegravir (Isentress(R)) in the treatment of HIV-infected adults - Canadian consensus guidelines.

Rachlis Anita A   Angel Jonathan B JB   Harris Marianne M   Shafran Stephen D SD   Therrien Rachel R   Tremblay Cécile C   Wainberg Mark A MA  

The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale 20090101 3


<h4>Background and objectives</h4>A meeting of a Canadian group with significant experience and knowledge in HIV management, consisting of five physicians, a pharmacist and an AIDS researcher, was convened. Their goal was to develop guidance for Canadian HIV-treating physicians on the appropriate use of raltegravir (MK-0518, Isentress(R), Merck Frosst Canada Inc) in HIV-infected adults.<h4>Methods</h4>Evidence from the published literature and conference presentations, as well as expert opinions  ...[more]

Similar Datasets

| S-EPMC5593243 | biostudies-literature
| S-EPMC6599830 | biostudies-literature
| S-EPMC7689616 | biostudies-literature
| S-EPMC7903287 | biostudies-literature
| S-EPMC1277045 | biostudies-literature
| S-EPMC8760827 | biostudies-literature
| S-EPMC4613743 | biostudies-literature
| S-EPMC4607777 | biostudies-literature
| S-EPMC3902823 | biostudies-literature
| S-EPMC3912854 | biostudies-literature